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Background. Plasmodium falciparum infection has been reported to increase human immunodeﬁciency virus
(HIV) viral load (VL), which can facilitate HIV transmission. We prospectively studied the impact of mild P falcip-
arum coinfection on HIV VL in Rwanda.
Methods. We measured plasma HIV VL at presentation with malaria infection and weekly for 4 weeks after
artemether-lumefantrine treatment in Rwandan adults infected with HIV with P falciparum malaria. Regression
analyses were used to examine associations between malaria infection and HIV VL changes. Samples with detectable
virus underwent genotypic drug-resistance testing.
Results. We enrolled 28 HIV-malaria coinfected patients and observed 27 of them for 5 weeks. Three patients
(11%) were newly diagnosed with HIV. Acute P falciparum infection had no signiﬁcant effect on HIV VL slope over
28 days of follow-up. Ten patients with VL <40 copies/mL at enrollment maintained viral suppression throughout.
Seventeen patients had a detectable VL at enrollment including 9 (53%) who reported 100% adherence to ARVs; 3 of
these had detectable genotypic drug resistance.
Conclusions. Unlike studies from highly malaria-endemic areas, we did not identify an effect of P falciparum
infection on HIV VL; therefore, malaria is not likely to increase HIV-transmission risk in our setting. However, rou-
tine HIV testing should be offered to adults presenting with acute malaria in Rwanda. Most importantly, we iden-
tiﬁed a large percentage of patients with detectable HIV VL despite antiretroviral (ARV) therapy. Some of these
patients had HIV genotypic drug resistance. Larger studies are needed to deﬁne the prevalence and factors associated
with detectable HIV VL in patients prescribed ARVs in Rwanda.
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Measuring human immunodeﬁciency virus (HIV) viral
load (VL) allows for the monitoring of antiretroviral
(ARV) therapy efﬁcacy, and the level of plasma HIV
viremia has been positively correlated with the risk of
perinatal and sexual transmission [1, 2]. Because HIV
and malaria are co-endemic and have high potential
for morbidity, it is important to understand the interac-
tions of these 2 infections. Plasmodium falciparum in-
fection has previously been reported to increase
transiently the VL of individuals infected with HIV
[3–6]. For example, Hoffman et al [4] prospectively ob-
served 27 patients in Malawi after successful treatment
for malarial infection and found a signiﬁcant decline in
HIV VL over 4 weeks. Using a similar study design, at
health centers in and around Kigali, Rwanda, we exam-
ined the effect of P falciparum infection on HIV VL
kinetics in adults infected with HIV.
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METHODS
The study protocol was approved by the institutional review
boards of the Albert Einstein College of Medicine and the
Rwanda National Ethics Committee.
Study Population
The study was conducted from January 2011 to April 2011 (the
local malaria transmission season). Adults with mild, sympto-
matic P falciparum infection seeking care at Nyacyonga,
Kabuye, Kagugu, and Masaka Health Centers and the Women’s
Equity in Access to Care and Treatment outpatient healthcare
clinics in Kigali, Rwanda were invited to participate. Mild
malaria was deﬁned as any level of symptomatic P falciparum
parasitemia without evidence of vital organ dysfunction [7]. In-
dividuals who had a positive malaria smear as well as a positive
HIV antibody test were offered enrollment in the study. Written
informed consent was obtained from all study participants.
Study Procedures
A positive P falciparum blood smear was conﬁrmed by 2 expe-
rienced microscopists, and a positive HIV antibody test was de-
termined using the Abbott Determine Rapid Test Strips for
HIV1/2 (Abbott Laboratories, Princeton, NJ) and the Uni-
Gold HIV Rapid Test (Trinity Biotech, Ireland). All patients
diagnosed with P falciparum infection were treated with arte-
mether-lumefantrine for 3 days. Patients newly diagnosed
with HIV were provided with linkage to care. For patients
with previously diagnosed HIV infection who were already in
care, medical records were reviewed to obtain history of oppor-
tunistic infections, ARV history, and recent CD4+ T cell counts.
Patients returned to clinic weekly for 4 additional study visits.
At enrollment and at each of the 4 weekly follow-up visits,
blood pressure, heart rate, temperature, respiratory rate, malaria
smear, and self-report of ARV adherence were obtained, and
plasma was collected by venipuncture using K2 EDTA blood col-
lection tubes (BD Vacutainer, Franklin Lakes, NJ). Plasma was
centrifuged and aliquoted within 2 hours of collection. Samples
were stored in ‒80°C at the National Reference Laboratory
(NRL) Division of the Rwanda Biomedical Center in Kigali be-
fore shipment to the Monteﬁore Medical Center (New York)
in a dry shipper. A complete blood cell count was performed
for each patient at the NRL, and percentage of parasitemia was
calculated from 5 different ﬁelds using the following formula:
number of asexual parasites
number of RBC
 
 100:
Plasma HIV VL assessments were performed at Monteﬁore
Medical Center using the Abbott RealTime HIVAssay (Abbott
Laboratories) with <40 copies/mL as the lower limit of detec-
tion. Patients with HIV VL <40 copies/mL at the time of
diagnosis of malaria infection and at days 14 and 28 after
artemether-lumefantrine treatment were considered to have
undetectable VL. Patients who had HIV VL >40 copies/mL
at any of these 3 predetermined time points were considered
to have detectable VL and had additional HIV VL measure-
ments performed on samples drawn at days 7 and 21 to
allow a more detailed analysis of their HIV VL trajectory.
Human Immunodeﬁciency Virus Resistance Testing Analysis
Genotypes were performed on samples with detectable HIV VL
to identify ARV drug-resistance mutations. Plasma samples
were further ultracentrifuged at 17 000 rpm for 1 hour at 4°C
before RNA extraction (QIAamp Viral RNA Minikit; Qiagen,
Valencia, CA), and the region encompassing the HIV protease
and reverse-transcriptase genes was ampliﬁed by nested prim-
ers. cDNA was synthesized (Superscript III One-step RT-PCR
with Platinum Taq Kit; Invitrogen Corp., Carlsbad, CA) follow-
ing the manufacturer’s instructions, and PCR products were se-
quenced (3730XL DNA Analyzer; Applied Biosystems, Foster
City, CA). Resistance mutations were deﬁned according to the
International AIDS Society-USA Panel and conﬁrmed by pub-
lished mutations in the Stanford HIV Drug Resistance database
(http://hivdb.stanford.edu/). Standard phylogenetic analyses
ruled out sequence contamination.
Data Analysis
Bivariate analysis was conducted using the Mann-Whitney U or
Wilcoxon rank-sign test for baseline continuous variables and
χ2 or Fisher’s exact test for baseline dichotomous variables
when appropriate. To identify predictors, such as participant
characteristics that signiﬁcantly correlated with HIV VL chang-
es, we applied random slope regression models to test the inter-
action between time and predictor. These random slope models
account not only for subject-by-subject variations in slopes but
also for correlations of repeated measures. We used SAS version
9.3 (SAS Institute Inc., Cary, NC) and STATA version 12 (Col-
lege Park, TX) to conduct these analyses. A 2-tailed P < .05 was
considered statistically signiﬁcant.
RESULTS
Twenty-eight Rwandan adults infected with HIV and presenting
with mild P falciparum infection were enrolled. Twenty-seven
patients completed the 5-week study. One patient was lost to fol-
low-up after the ﬁrst visit and was excluded from analyses. For
the 27 remaining patients, median age was 34 years (interquartile
range [IQR], 29–40) and 52% were men. Follow-up blood smears
were negative for malaria parasites at each time point.
Human Immunodeﬁciency Virus Disease
At enrollment, 24 of the 27 patients were already known to be
infected with HIV, and 3 patients (11%) were newly diagnosed.
Eighteen patients reported being prescribed ARVs, and 24
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patients reported being prescribed co-trimoxazole; all patients
reported 100% adherence to medications. All ARV regimens in-
cluded a combination of nucleoside reverse-transcriptase inhib-
itors (NRTIs) and a non-NRTI (NNRTI) (efavirenz or
nevirapine). Median CD4+ T cell count was 484 cells/μL
(IQR, 303–629), and for patients with known HIV infection
at enrollment these values were recorded from within a median
of 5 months (range, 3–19 months) before study entry; 1 newly
diagnosed patient had no CD4+ T cell count available. Presenting
symptoms included fever, myalgias, headache, joint pain and gas-
trointestinal symptoms, and lack of clinical indicators of severe
malaria. The geometric mean of percent parasitemia was 0.37%.
Ten of 27 patients were categorized as having an undetectable
VL (<40 copies/mL) at enrollment and at days 14 and 28. Two of
the patients with undetectable HIV VL did not report taking
ARVs. The remaining 17 patients had detectable VL. There were
no signiﬁcant differences between the group with undetectable VL
and detectable VL with regard to age, sex, number of days ill, tem-
perature, hematocrit, and percentage of parasitemia. The group
with undetectable VL had signiﬁcantly higher CD4+ T cell (596
cells/µL vs 395.5 cells/µL, P = .01) and leukocyte counts (5250
cells/µL vs 3050, P value = .006) compared with the group with de-
tectable VL, regardless of ARV prescription history (Table 1).
Effect of Plasmodium falciparum Infection on Human
Immunodeﬁciency Virus Viral Load
Median VL among those with detectable virus was 25 641 cop-
ies/mL (IQR, 686–108 541) at enrollment and 23 713 copies/mL
(IQR: 268–243 567) at day 28. Of the 17 patients who complet-
ed the study and had at least 1 detectable HIV VL measured at
enrollment, day 14 or day 28, we obtained VL from days 7 and
21 in 16 of them. Human immunodeﬁciency virus VL measure-
ments did not change signiﬁcantly over the 5-week course of the
study: there were no signiﬁcant changes in the median log10
HIV VL from the samples collected at enrollment to day 7
post-malaria treatment (P value = .09), day 14 (P = .50), day
21 (P = .79), or day 28 (P = .75). To further investigate the effect
of P falciparum infection on HIV VL kinetics, we performed re-
gression analyses using both the random slope model and
mixed effects linear model. These models also found no signiﬁ-
cant change in HIV VL over time (Figure 1).
To identify individuals who had a signiﬁcant change of HIV
VL after successful treatment for P falciparum, we used individ-
ual regression analysis and identiﬁed a single patient who had a
signiﬁcant decrease in HIV VL from enrollment to day 28
(P = .014). At enrollment, this patient, who reported taking
ARVs, had a 0.53% parasitemia, a CD4+ T cell count of 327
cells/μL, and an HIV VL of 1089 copies/mL that decreased to
149 copies/mL at day 28. In contrast, 1 patient not on ARVs
with an enrollment CD4+ T cell count of 98 cells/μL had a sig-
niﬁcant increase in HIV VL over the study period, with 62 cop-
ies/mL at enrollment and 3 × 106 copies/mL by day 28 (P = .04).
It should be noted that this patient was diagnosed with active
tuberculosis 2 weeks after study enrollment.
Drug Resistance Mutations
To determine whether drug-resistant strains were present and
associated with HIV viremia, we carried out genotyping for
ARV drug-resistance mutations on the 17 samples with detect-
able HIV VL (Table 2). Two of these samples could not be suc-
cessfully genotyped. Genotypic analyses revealed that 12 patients
Table 1. Characteristics of the Cohort By Detectable and Unde-
tectable (<40 copies/mL) HIV VL Status*
Characteristic
Undetectable
HIV VL Detectable HIV VL P
Value(n = 10) (n = 17)
Age (years) 36.5 (31.3–40.8) 31 (29–40) .48
Sex (% females) 60% 41% .44†
Days Ill 4.5 (2.8–7.0) 3.0 (2.3–7.0) .53
Parasitemia (%) 0.41 (0.39–5.0) 0.35 (0.28–0.44) .56
Temperature (°C) 37 (36.7–37.6) 37 (36.4–37.2) .38
Hematocrit 42·2 (40.8–48.2) 41 (37.4–42.8) .20
WBCs (cells/µL) 5250 (4175–8000) 3050 (2475–4825) .01
Lymphocytes
(cells/µL)
1640 (1418–1868) 1340 (940–1770) .24
CD4+ T cells
(cells /µL)
596 (455–758.5) 395.5 (240–519.5) .01
% on ARV 80% 53% .23†
% on
Cotrimoxazole
100% 82% .27†
Abbreviations: ARV, antiretroviral; HIV, human immunodeficiency virus; VL,
viral load; WBC, white blood cell count.
* Median and interquartile ranges are provided: geometric mean is reported for
parasitemia. P Values are calculated using the Mann-Whitney U test.
† Fisher’s exact.
Figure 1. Human immunodeﬁciency virus RNA concentrations at time of
mild P falciparum infection (0), and weekly for 4 weeks. Regression anal-
yses using both the random slope model and mixed effects linear model
found no signiﬁcant change over time. Box and whisker plots represent the
median and interquartile ranges.
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(80%) did not have clinically relevant drug-resistance mutations,
1 sample (7%) had a single NNRTI mutation, and 2 samples
(13%) demonstrated both NRTI and NNRTI mutations. All 3 pa-
tients in whom drug-resistant mutations were found reported
current ARV use. Four samples were found to harbor minor pro-
tease inhibitor (PI) mutations that are considered naturally oc-
curring polymorphisms (no patients had prior PI exposure).
DISCUSSION
Prior studies have reported that P falciparum infection may
transiently increase HIV VL [2–4, 6]. This had, until now,
only been evaluated in highly endemic areas and before the
availability of ARVs. To determine whether P falciparum infec-
tion impacts HIV VL trajectories in Rwanda, we carried out a
prospective study and, in contrast to Hoffman et al [4], we did
not detect a decline in HIV VL after successful treatment for
P falciparum, suggesting that malaria does not increase HIV
VL in our setting.
Our patients manifested very mild illness, with normal tem-
peratures and hematocrit, and this may explain the lack of effect
of malaria infection on HIV VL. Prior studies have shown that
high parasitemia associated with fever are associated with the
greatest change on HIV VL and that the inﬂammatory cytokine
tumor necrosis factor drives HIV replication during malaria
[3, 8]. In addition, a pre-malaria infection VL would provide
additional data to examine the effect of malaria on VL trajec-
tory. Our study is one of the ﬁrst to examine the HIV VL-
malaria interaction in patients on ARV. Whether malaria in-
fection can cause breakthrough VL during ARV suppression
will have to be studied in regions where malaria infection in-
creases HIV VL in ARV-naive patients. The 1 patient who
demonstrated a signiﬁcant increase in HIV VL in our study
had active TB, and the association of TB with an increase in
HIV VL is well documented [9, 10].
An unanticipated and important ﬁnding from our study was
that all patients with previously diagnosed HIV infection who
were prescribed ARVs reported 100% adherence, yet 8 of
them had detectable HIV VL. The 3 samples that had NRTI
or NNRTI drug-resistance mutations were all among the
ARV-prescribed group, suggesting that in a fraction of cases,
ARV resistance is leading to loss of HIV viral suppression.
Among those with ARV resistance mutations, the genotyping
data identiﬁed K65R, K70R, M184V, and K103N, which have
been previously described in Rwanda [11]. Two patients
(14%) had both NRTI and NNRTI mutations. Inferences re-
garding the epidemiology of HIV drug resistance in Rwanda re-
quire larger population-based studies [12]. The lack of HIV
drug-resistance mutations among the majority of those report-
ing 100% ARV adherence and who had a detectable HIV VL
suggests that lack of adherence may be a contributor to uncon-
trolled viremia [13]. Two patients in our study who had unde-
tectable VL reported no current use of ARVs. Although elite
control may be a possibility, recent studies suggest that self-
report of no ARVs may be inaccurate [14, 15]. Larger studies
in Rwanda are needed to deﬁne the prevalence of and factors
associated with detectable HIV VL in patients prescribed
ARVs to improve clinical outcomes.
We identiﬁed 3 new HIV infections in patients presenting
with mild P falciparum infection. Prior studies have shown
that persons infected with HIV have a higher rate of malaria in-
fection [16–18]. It is conceivable that in some cases, patients′
symptoms (such as fever and myalgias) were related to HIV ret-
roviral syndrome rather than malaria, and their malaria infection
was subclinical. A study from Uganda found that 11% of patients
presenting with malaria-like illness had HIV [19]. Our study was
not designed to determinewhether adults infected with HIV have
a higher rate of malaria infection in Rwanda, but offering routine
HIV testing in adults presenting with malaria infection, or symp-
toms consistent with malaria, could be beneﬁcial in linking pa-
tients to HIV care and improving outcomes.
CONCLUSIONS
This prospective study of HIV-infected Rwandan adults coin-
fected with P falciparum did not identify malaria-associated
changes in HIV VL. Our ﬁndings are in contrast to previous re-
ports from areas more highly malaria-endemic, where malaria
Table 2. HIV Drug-Resistance Genotypes in Samples With
Detectable HIV Viral Loads
Patient ID NRTI NNRTI PI Major PI Minor
No ARV
52 None None None L10I
18 None None None None
25 None None None None
28 None None None None
41 None None None None
65 None None None None
81 None None None None
Prescribed ARV
40 D67G, K70R,
M184V, K219Q
Y188L,
K238N
None None
68 M184V Y181C,
G190A
None None
30 None K103N None None
22 None None None L10V
23 None None None L33I
76 None None None L10V
53 None None None None
57 None None None None
Abbreviations: ARV, antiretroviral; HIV, human immunodeficiency virus; ID,
identification; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI,
nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
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coinfection was found to be associated with a transient rise in
HIV VL. The key observation in our cohort was that the major-
ity of patients prescribed ARVs and reporting 100% adherence
had detectable HIV VL. Human immunodeﬁciency virus drug-
resistance mutations could account for lack of viral suppression
in a subset of patients, but suboptimal adherence may also be a
contributor to uncontrolled viremia. Improved adherence strat-
egies, HIV VL monitoring, and drug resistance testing for pa-
tients receiving ARVs are needed to inform clinical practice
and improve patient outcomes in Rwanda. In our cohort, 11%
of coinfected patients were newly diagnosed with HIV: addi-
tional studies are needed to determine whether malaria infec-
tion in Rwandan adults is more prevalent among individuals
infected with HIV. If HIV infection is more prevalent in adults
with malaria then HIV testing should be offered to all adults
presenting with malaria in Rwanda.
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